Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer


如何引用文章

全文:

详细

The data of the efficacy and safety regorafenib in the treatment of 7 patients with metastatic colorectal cancer (mCRC) refractory to treatment with cytostatics and monoclonal antibodies - blockers EGFR and VEGF were analyzed. The maximum anti-tumor effect in 1 patient had partial remission, in 6 - stabilization. The duration of progression-free period from start of treatment regorafenib ranged from 1.5 to 6 months. 3 patients continued antitumor therapy after progression, 3 - had the symptomatic therapy after progression, 1 - had stabilization within 4 months and continued therapy of regorafenib. Toxic effects of therapy were nausea, vomiting, diarrhea, complications of the skin, temperature reaction, increased blood pressure, dysphonia. The most clinically significant adverse events were changes in laboratory parameters in 3 patients (increase of ALT, AST and bilirubin), that resulted an interruption in the treatment and correction of the dose. The use of regorafenib in mCRC ensure adequate tumor control, and is characterized by mild toxicity that is relevant for pretreated patients resistant to other forms of anticancer therapy.

作者简介

O Kit

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

Email: rnioi@list.ru
д-р мед. наук, проф., дир. ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

L Vladimirova

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., рук. отд. лекарственного лечения опухолей ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

N Abramova

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд. лекарственного лечения опухолей ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

A Storozhakova

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, врач отд-ния противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

I Popova

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд. лекарственного лечения опухолей ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

N Tikhanovskaya

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, врач-онколог отд-ния противоопухолевой лекарственной терапии № 1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

A Lyaynova

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

врач-онколог отд-ния противоопухолевой лекарственной терапии № 1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

L Ryadinskaya

Rostov Research Institute of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, врач-онколог отд-ния противоопухолевой лекарственной терапии № 1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

参考

  1. Jemal A. Global cancer statistics. CA Cancer J Clin 2011; 2 (61): 69-90.
  2. Кит О.И., Владимирова Л.Ю., Абрамова Н.А. и др. Опыт применения моноклональных антител - блокаторов EGFR в лечении метастатического колоректального рака. Фарматека. 2015; 18 (311): 24-8.
  3. Van Cutsem E, Humblet Y, Gruenberger T et al. Cetuximab dose - escalation study in patients with nCRC with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): preliminary PK and efficacy date of a randomized study. Proc. of ASCO 2007. Abstract 237.
  4. Van Cutsem E, Peeters M, Siena S et al. Open - label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy - refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64.
  5. Vladimirova L.Y, Kit O.I, Nikipelova E.A, Abramova N.A. Results of monoclonal antibodies against EGFR-receptors application in patients with metastic colorectal cancer. J Clin Oncol 2013; 31 (15S) part I of II: 800S.
  6. Price T.J, Peeters M, Kim T.W et al. Panitumumab versus cetuximab in patients with chemotherapy - refractory wild - type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open - label, non - inferiority phase 3 study. Lancet Oncol 2014; 15 (6): 569-79.
  7. Khattak M.A, Martin H, Davidson A, Phillips M. Role of first - line antiepidermal growth factor receptor therapy compared with anti - vascular endothelial growth factor therapy in advanced colorectal cancer: a meta - analysis of randomized clinical trials. Clin Colorectal Cancer 2015; 14 (2): 81-90.
  8. Kopetz S, Hoff P.M, Morris J.S et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28 (3): 453-9.
  9. Wilhelm S.M, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129 (1): 245-55.
  10. Grothey A, Van Catsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo - controlled, phase 3 trial. Lancet 2013; 381: 303-12.
  11. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, doubleblind, placebo - controlled, phase 3 trial. Lancet Oncol 2015; 16: 619-29.
  12. Артамонова Е.В. Новые возможности терапии интенсивно - предлеченных пациентов с метастатическим колоректальным раком. Мед. совет. 2016; 10: 24-32.
  13. Секачева М.И., Багмет Н.Н. Применение регорафениба при метастатическом колоректальном раке в реальной клинической практике // Современная онкология. 2016; 18 (3): 43-7.
  14. Van Cutsem E, Ciardiello F, Seitz J-F et al. Results from the large, open - label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol 2015; 26 (Suppl. 4): Iv117-iv121.
  15. Abou-Elkacem L, Arns S, Brix G et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013; 12 (7): 1322-31.

版权所有 © Consilium Medicum, 2017

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##